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ABSTRACT
Breast cancers are the most common cancer-affecting women; critically the 
identification of novel biomarkers for improving early detection, stratification and 
differentiation from benign tumours is important for the reduction of morbidity and 
mortality.
To identify and functionally characterise potential biomarkers, we used mass 
spectrometry (MS) to analyse serum samples representing control, benign breast 
disease (BBD) and invasive breast cancer (IDC) patients. Complementary and 
multidimensional proteomic approaches were used to identify and validate novel 
serum markers.
Annexin A3 (ANX A3) was found to be differentially expressed amongst different 
breast pathologies. The diagnostic value of serum ANX A3 was subsequently validated 
by ELISA in an independent serum set representing the three groups. Here, ANX A3 
was significantly upregulated in the benign disease group sera compared with other 
groups (P < 0.0005).
In addition, paired breast tissue immunostaining confirmed that ANX A3 
was abundantly expressed in benign and to a lesser extent malignant neoplastic 
epithelium. Finally, we illustrated ANX A3 expression in cell culture lysates and 
conditioned media from neoplastic breast cell lines, and its role in neoplastic breast 
cell migration in vitro.
This study confirms the novel role of ANX A3 as a mammary biomarker, regulator 
and therapeutic target.
INTRODUCTION
Breast cancer is the most common malignancy and 
the second leading cause of cancer related death in women 
[1–3]. Every year nearly 1.4 million women are diagnosed 
with the disease [4]. Early diagnosis and more effective 
treatment regimens have led to a paradoxical improvement 
of survival rates despite an increasing breast cancer 
incidence over the last few decades [5–7]. Nonetheless, a 
reported variation in screening mammography sensitivity 
between 74–85% suggests limitations to this technique 
[8]. Although screening programs lead to an estimated 
15% reduction in breast cancer mortality, they were 
subsequently shown to be associated with 30% risk of 
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over-diagnosis and treatment [9–11]. Prediction and 
stratification of breast disease at an early stage would 
further improve patients’ outcome and quality of life. In 
particular, early diagnostic markers allowing personalised 
management for women at the greatest risk are needed. 
Markers that reduce the incidence of “missed” or delayed 
breast cancer diagnosis would reduce the rate of excessive 
surgical and percutaneous benign biopsies thus improving 
diagnostic pathways, screening programs and patients’ 
well-being. Existing biochemical markers are also of 
limited value in assessing and stratifying breast cancer risk 
in the healthy population [12–15].
Molecular profiling studies are anticipated to 
improve the understanding of biological expression and 
characterization of cancer patients according to their 
individual risk of disease development, progression 
and therapeutic response [16]. This will also aid the 
development of novel multimodal therapeutic strategies 
improving disease outcome. Proteins are the main 
biological effectors in normal and cancer cells and 
hence can potentially serve as functional biomarkers and 
treatment targets. As such, proteomic profiling constitutes 
an ideal tool in the identification of key molecular 
evidence supporting current clinical practices.
In this study we sought to identify new diagnostic 
and stratification biomarkers of breast cancer by serum 
proteomic profiling. Our primary aims were to identify 
novel discriminatory biomarker(s) between age-matched 
groups representing controls, benign breast disease, and 
invasive ductal carcinoma of the breast, and to determine 
their potential clinical utility. Using a combination of mass 
spectrometry (MS) methods in an intra-laboratory setting 
with ELISA validation analysis, we identified a potential 
novel serum marker, Annexin A3. Paired breast tumour 
tissue immunostaining analysis confirmed the validity 
of this marker at the tissue level. Finally, we confirmed 
that ANX A3 was expressed and regulated migration in 
neoplastic breast cell lines. This study provides insight 
into a potential novel marker of breast tumourigenesis and 
its prospective role in clinical diagnostics and therapeutics.
RESULTS
Biomarker discovery and validation
MS profiling was conducted in two centers adopting 
MALDI-TOF MS-MS, SELDI-TOF MS, Infusion FT-
Orbitrap MS2 and Ion-trap LC-MS2 analyses. The initial 
statistical analysis was performed as an independent 
single institute study and MS signals that demonstrated 
significant fold-change differences were cross-compared 
between the two institutes. A total of 1041 samples 
including 630 healthy controls, 219 invasive ductal 
carcinoma (IDC) and 192 benign breast disease (BBD) 
were analysed between the two sites.
MS analyses detected an ion peak at m/z 15.9 kDa 
which was over-expressed in the benign disease compared 
to the healthy control group (P = 0.019) (Figure 1a). The 
intensity of this ion was observed to be stronger in the 
benign disease compared to the IDC group, however, 
significant differential expression was not detected 
between either the IDC versus BBD (P = 0.43), or the 
IDC versus control groups (P = 0.90).
Biomarker purification, identification and 
verification
ANX A3 was identified as the 15.9kDa marker 
following two dimensional purification using free flow 
electrophoresis isoelectric focusing (FFE-IEF) and one 
dimensional gel electrophoresis (SDS PAGE), tryptic 
digestion and sequencing of the equivalent 15.9kDa gel 
band (Figure 1b and Supplementary Files S2, S3).
To further verify the ANX A3 identity, 
immunoprecipitation (IP) was performed to deplete ANX 
A3 from the test serum sample, and was then followed by 
MS analysis of the resulting extract. The m/z peak at 15.9 
kDa was absent from the ANX A3 depleted sample and 
highly enriched in the ANX A3 IP eluate confirming the 
identity of this biomarker as ANX A3 (Figure 1c).
Immuno-validation of ANX A3 expression in 
serum
To further assess the role and performance of ANX 
A3 as a clinical marker, ELISA validation of representative 
pooled serum samples from each group (n = 14) followed 
by additional randomly selected serum samples (n = 51) 
were conducted. The pooled serum ELISA validation 
confirmed significant ANX A3 overexpression in BBD 
compared to both IDC and controls (P < 0.05) (Figure 1d). 
Moreover, the individual serum sample ELISA validation 
has also confirmed ANX A3 levels to be higher in 
benign disease compared to the healthy control samples 
(P < 0.0005), consistent with our MS findings. Here, the 
ANX A3 levels were also significantly raised in benign 
disease compared to invasive breast cancer patients 
(P < 0.0005) (Figure 2a.). The levels of serum ANX A3 
in benign disease (0.915 ng/ml, 95% CI 0.56 - 0.87) was 
significantly higher than both control (0.54 ng/ml, 95% CI 
0.23 - 0.84), and invasive breast cancer (0.57 ng/ml, 95% 
CI 0.44 - 0.69) groups.
ANX A3 expression in breast cancer and benign 
breast human cell lines
We tested the hypothesis that breast tumour cells 
secreting ANX A3 could explain the raised ANX A3 levels 
in benign and malignant breast neoplasms. Here, we used 
ELISA to quantify ANX A3 expression and secretion in 
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neoplastic breast cell lines. The ANX A3 quantification 
confirmed that MCF7, T47D, MDA MB231, SKBR3, ZR 
75–1 and HUMA121 human breast cells expressed and 
secreted ANX A3 (Figure 2b).
Abundant ANX A3 expression in benign breast 
disease tissue samples
We next investigated ANX A3 expression at the 
tissue level by immunohistochemistry (IHC) using paired 
breast tissue samples analogous to sera used in the MS 
analysis. We analysed 27 randomly selected breast tissue 
samples corresponding to serum samples used in the 
earlier MS analysis (ten cancer, eleven benign disease and 
six normal breast tissue). Two histopathologists performed 
a blinded analysis independently using a semi quantitative 
scoring system (ANX A3 index) based on the percentage 
and intensity of IHC staining.
The IHC analysis showed that ANX A3 expression 
was predominantly cytoplasmic and was substantially 
over-expressed in benign breast disease and to a lesser 
extent in invasive breast cancer tissue compared with 
healthy controls (χ2 = 6.12, P = 0.045) (Figure 2c). 
Here, 66% of healthy breast tissue samples showed 
weak or absent ANX A3 staining. In comparison, 91% 
of benign breast disease tissue samples stained highly 
for ANX A3. Among malignant disease cases, 30% of 
cancer tissues had high ANX A3 expression profiles 
with the remaining cases having moderate or no ANX 
A3 expression.
ANX A3 promotes cell migration 
in MCF-7 cells
We investigated the effect of silencing ANX A3 
on cell proliferation and migration in the MCF7 breast 
cancer cell line. Silencing of ANX A3 was achieved 
using ANX A3 siRNA (Figure 3a). ANX A3 silencing 
significantly inhibited the ability of MCF7 cells to 
migrate across the trans-well membrane (Figure 3b 
& 3c). However, ANX A3 silencing did not affect cells 
proliferation. This confirmed that the observed decrease 
in migrating cells was not due to an anti-proliferative 
effect (Figure 3d).
Figure 1: Bottom up proteomic analysis identified ANX A3 as a potential breast cancer marker. a. Semi-quantitative 
MS expression profiling analysis was performed on serum samples in two centres (UoS and SGUL). Bars represent mean peak 
intensity ± standard error (SE) for the 15.9 kDa putative peak marker detected by MS analysis. Significant biomarker up-regulation in 
the benign disease group compared to controls and non-significant higher levels as compared to cancer sera fractions were illustrated. 
(Mann-Whitney U test *P < 0.05) b. Unfractionated serum (A), a series of different consecutively pooled and vacuum dried FFE 
fractions (B–E) were run on 1D-GE (4% tricine/10% SDS/16% polyacrylamide) gel at 100 V for 4 h at room temperature to purify 
the candidate BBD biomarker at 15.9 kDa. This approach was used to increase the biomarker concentration and reduce sample 
complexity. The dominant 15.9 kDa protein band (white arrow/box) was identified by infusion FT-Orbitrap MS2 and Ion-trap LC 
MS2 as ANX A3. c. IP-MS verification of the 15.9 kDa marker identified as ANX A3. Antibody capture of ANX A3 was performed 
using monoclonal antibody (sc-134260, Santa Cruz). The antibody was linked to μMACS protein A/G columns (Miltenyi Biotec) 
and incubated with pooled serum fractions containing ANX A3. The bars illustrate MS profiles of ANX A3 expression in serum 
fraction, along depleted specimen and the enriched ANX A3 IP eluate respectively. The depletion of ANX A3 in the IP MS samples 
and subsequent enrichment in the eluate spectra confirmed the identity of the 15.9kDa peak as ANX A3. d. ANX A3 levels in pooled 
serum fractions measured by quantitative ELISA. ANX A3 over expression in control (n = 5) compared to both benign disease 
(n = 4) and invasive breast cancer (n = 5) groups was illustrated in this independent validation cohort. Bars represent the mean ANX 
A3 levels ± standard error (SE). *P < 0.05.
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Figure 3: ANX A3 silencing inhibits migration of MCF7 cells. MCF7 cells were transfected with 10 nM ANX A3-siRNA using 
Oligofectamine™ (Invitrogen) as per manufacturer’s instructions. a. At indicated time points cell lysates were assessed by immunoblotting 
for ANX A3 and GAPDH as a loading control. The signal was analysed using a LICOR Odyssey imaging system. ANX3 was successfully 
silenced for the duration of the experiment. b. ANX A3 was silenced in MCF7 cells and cells were seeded onto the upper layer of the 
transwell cell permeable membrane transwell. At indicated time points cells were fixed, cells on the upper layer of the transwell membrane 
were removed whereas cells that had migrated to the underside of the transwell membrane were stained with DAPI stain and counted. ANX 
A3 visibly reduced the number of cells that migrated to the underside of the transwell membrane. c. Quantification of migration showed 
that migration was significantly reduced in ANX A3-silenced cells at both 48 h (*p < 0.01, n = 3) and 72 h (*P < 0.001, n = 3). d. 5000 
cells were seeded into wells of 24 well plates, fixed at indicated time points and stained with DAPI central fields of view were images and 
cells counted. No difference in proliferation was observed between ANX A3silenced cells and control cells treated with ntg-siRNA (n = 3).
Figure 2: Immuno-validation and tissue correlation of ANX A3. a. ANX A3 levels in pooled serum fractions measured by 
quantitative ELISA. ANX A3 over expression in benign disease (n = 21) compared to both control (n = 14) and invasive breast cancer 
(n = 16) groups was illustrated in this independent validation cohort. Bars represent the mean ANX A3 levels ± standard error (SE). The 
ANX A3 ELISA kit detection specificity was assessed using ANX V recombinant protein as a negative control. Here, serum ANX A3 was 
significantly over expressed in the BBD compared to the control and IDC groups. ***P < 0.0005. b. Annexin A3 levels in the cell lysates 
(black bars) and culture medium (white bars) from six neoplastic human breast cell lines were measured by ELISA. ANX A3 expression 
was confirmed by ELISA in malignant cell lines (MCF7, ZR 75–1. T47D, SKBR3, MDA MB231) and conditioned media. A lower ANX 
A3 expression was detected in the non-malignant Huma121 cells and conditioned media. c. Representative photomicrographs of Annexin 
A3 immunohistochemistry in paired breast tissue corresponding to serum samples used in the MS analysis. A and B represent fibroadenoma 
(original magnification x200) with strong epithelial ANX A3 staining (B) C and D represent invasive carcinoma (x200) where the tumour is 
surrounding a benign duct. The tumour shows weak tumour ANX A3 expression compared to the benign area. E and F High power (x400) 
images of invasive ductal carcinoma showing weak annexin expression. G and H normal breast lobule demonstrating annexin expression. 
Overall, the BBD tissue ANX A3 staining was significantly higher than the other groups (P < 0.05).
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DISCUSSION
In this study we mined for potential novel breast 
cancer serum biomarkers. Multi-platform MS analyses and 
validation of matched serum samples representing healthy 
volunteers, benign breast disease and invasive breast 
cancer groups was adopted to minimize false positive 
discovery risk. Following an extensive verification phase, 
a potential new breast cancer serum biomarker was 
detected and subsequently identified as human Annexin 
A3 (ANX A3), a phospholipid and calcium binding 
protein. This result was confirmed by ELISA validation 
analysis involving serum samples from an independent 
cohort representing the same three subject groups.
Current serum and hormonal markers for breast 
cancer are non-ideal and there is a need for reliable serum 
biomarkers for the prediction, diagnosis and stratification 
of breast tumours. Proteomics can significantly contribute 
in this regard. This study constitutes the first reported 
identification of higher levels of serum ANX A3 in BBD 
compared to both controls and invasive breast cancer 
patients. Screening mammography is reported to result in 
increased benign breast biopsies and some of these fail to 
confirm cancer [17–19]. Moreover, higher total biopsy rates 
are not associated with improved cancer detection [20]. 
In this context, serum ANX A3 levels could potentially 
complement and enhance mammographic screening 
performance and reduce the incidence of benign biopsies.
Annexin A3 is a member of a structurally 
homologous, but nonetheless functionally diverse annexin 
family [21]. ANX A3 is proposed to play anti-apoptotic, 
angiogenic and growth regulatory roles [22–24]. In 
addition, ANX A3 was shown to be differentially expressed 
in different malignancies in a tissue specific manner 
[25, 26]. Albeit an early finding, this work provides new 
evidence that ANX A3 expression may shed new light on 
the underlying biology of human breast neoplasms.
In this study, the majority of the benign breast disease 
samples represented non-proliferative breast conditions. 
Although the study design and cohort number are both 
limiting factors in evaluating the role of ANX A3 in reducing 
benign breast biopsies rate, as such, this could be a venue for 
further exploration. An interesting phenomenon demonstrated 
in this work was the over expression of ANX A3 in benign 
breast conditions as well as breast cancer samples compared 
to healthy women. Here, the benign disease group ANX A3 
expression was shown to be higher than the cancer group both 
on the serum and tissue levels. The cancer serum and tissue 
samples on the other hand had higher ANX A3 expression 
compared to controls. Although the molecular mechanism 
explaining such trend remains unclear, a similar benign 
disease tissue ANX A3 over expression trend was found in 
benign prostate hypertrophy (BPH) relative to prostatic in 
situ neoplasms (PIN) and invasive prostatic carcinoma tissue 
samples [27, 28]. Secreted ANX A3 has also been shown to 
correlate with ovarian cancer chemotherapy resistance [29]. 
The specific molecular etiology of ANX A3 regulation in 
hormone-associated cancers thus warrants further evaluation. 
Equally, the expression behavior of ANX A3 in ductal 
carcinoma in situ (DCIS) and different IDC molecular sub 
groups (basal, ERBB-2 and luminal) necessitates larger sub-
entity focused studies.
Here, we also demonstrated a similar ANX A3 
over expression in benign and malignant breast tissue 
correlating to serum samples from this cohort. Although 
the over expression in malignant tissue immunostaining 
was more pronounced compared to the serum, serum is 
a multi-parametric reservoir of multiple organ systems 
that undoubtedly introduce several confounding factors 
negating its absolutely linear correlation with the tissue 
findings. The illustration of a consistent expression 
trend among the groups on the serum and tissue levels is 
intriguing. Based on our previous results, we hypothesized 
that elevated serum levels of ANX A3 protein were due 
to its increased secretion from neoplastic breast cells 
into the systemic circulation. To support this hypothesis, 
six neoplastic mammary cell lines were confirmed to 
consistently secrete ANX A3 as detected in their lysates 
and their supernatant culture media. Although the profiles 
of cell expression/secretion in vitro are rather difficult to 
compare to the in vivo cellular behavior, such consistency 
in expression/secretion trend across several neoplastic cell 
lines is more likely to reflect a candid biological path. The 
potential functional role of ANX A3 in mammary malignant 
transformation and/or progression is interesting as ANX A3 
was defined previously as an independent prognostic factor 
related to neoplastic progression [30]. In addition, ANX A3, 
along with ANX A2 were found to be marker components 
of exosomes secreted by neuroblastoma cell lines [31]. This 
observation further strengthens the notion that ANX 3 is 
secreted and enriched by exosome mediated processes.
Finally, the potential functional role of ANX A3 
in neoplastic breast activity was illustrated by halted 
migration despite maintained proliferation in the ANX 
A3 silenced MCF7 cell line. Although this evidence is 
of limited translational value at this stage, together with 
recent evidence of a neoplastic relevance of ANX A3 in 
breast cancer [32], it denotes another significant functional 
indication of a tumourigenic role of ANX A3 in breast 
cancer. As such, ANX A3 could be a potential therapeutic 
target decelerating breast cancer metastasis. Exploring 
the ANX A3 activity in various breast cancer cell lines 
representing the disease sub groups is deemed essential.
In conclusion, the present study provides more 
evidence of a potential role for ANX A3 as a serum and 
tissue breast cancer marker. ANX A3 is expressed and 
secreted by neoplastic mammary cells, and its inhibition 
halts migration in breast cancer cells. Large scale 
prospective studies together with long term follow-up and 
detailed molecular analysis are required to elucidate the 
role and mechanism(s) by which ANX A3 might impact 
breast pathology, diagnostics, and tumourigenesis.
Oncotarget21426www.impactjournals.com/oncotarget
MATERIALS AND METHODS
Patients
Serum samples were collected as part of the 
proteomic analysis in a breast screening study involving 
breast disease and healthy volunteers from the Wessex 
region (UK) prior to any intervention. Sample collection 
was approved by the Southampton General Hospital NHS 
Trust Ethics Committee (Ethical Approval 05/Q1702/13, 
R&D reference RHMCAN0392) and informed consent 
was obtained from all participants in the study. Samples 
from 630 controls, 192 benign breast disease (BBD) and 
219 invasive breast cancer (IDC) patients were used in 
this study.
Serum proteomic profiling and biomarker 
identification
Both the SELDI and MALDI-TOF MS profiling 
platforms were used for the MS profiling analysis and 
biomarker validation. Multidimensional proteomic bio-
marker purification, identification and verification using 
free flow and gel electrophoresis, FT Orbitrap and LC 
MS/MS sequencing were then implemented for bona 
fide identification of potential biomarkers as described in 
Supplementary Materials and Methods (File S1).
ANX A3 ELISA and immunohistochemistry 
validation
ANX A3 measurements in serum fractions and cell 
lysate/media were performed using commercially available 
sandwich ELISA kits according to the manufacturers’ 
protocol (USCN Life Science, E94786Hu and CUSABIO 
Biotech Co. CSB-E12157 h). In addition, ANX A3 
expression in formalin fixed paraffin embedded breast 
tissue blocks was performed by two pathologists applying 
an ANX A3 score as described in the Supplementary 
Materials and Methods.
Evaluation of the molecular role of ANX A3 in 
breast cells
Six neoplastic human breast cell lines (HUMA121, 
MCF7, T47D, MDA MB231, SKBR3 and ZR 75–1) 
representing different molecular subgroups of breast 
neoplasms were cultured to analyse their ANX A3 
expression and secretion. Moreover, ANX A3 expression 
was manipulated in MCF7 cells to assess its potential 
effect on mammary tumourigenesis.
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